PATENT CLAIM ANALYSIS

Application Number: 15771914
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "253100"]

Abstract:
Disclosed is a mast cell inhibitor, a pharmaceutical composition and a method for the treatment of patients afflicted with Parkinson's disease, wherein the patients are treated with a tyrosine kinase inhibitor or mast cell inhibitor, in particular masitinib, or a compound selected from imatinib, cromolyn sodium, midostaurin, BLU-285, bosutinib, ibrutinib, LAS189386, DP-2618, fostamatinib, dasatinib, sunitinib, axitinib, pazopanib, and toceranib or a pharmaceutically acceptable salt or solvate thereof, optionally in combination with at least one pharmaceutically active ingredient.

Claim (Index 20):
A method for the treatment of Parkinson's disease in a mammal in need thereof, said method comprising administering to the mammal masitinib or a pharmaceutically acceptable salt or solvate thereof.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 91.0
- Lexical Diversity: 1.59016
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15545800', '14957201', '13640857', '13983626', '14433198']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7755128644742658
- 35 USC 102 Novelty (BERT): 0.5314502107513244
- Combined Prediction Score: 0.7511065991019716
- Mean Citation Score: 312.0495279999999
- Max Citation Score: 361.68576
- Similarity Product: 251.76727892097472

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test